alopecia

Posts

Alopecia Treatment Market Insights

Alopecia Treatment Market

Alopecia Treatment Market Poised to Grow at a CAGR of XX% Between 2020 – 2030

Alopecia Treatment Market research report is a professional and an in-depth study available on the market size, share, growth, trends, in addition to industry evaluation. Alopecia Treatment Market report provides a thorough analysis and competitive analysis by region and added main information like a manufacturing process, raw material and equipment suppliers, various manufacturing associated costs, revenue, historical and futuristic cost, demand and supply data.

Moreover, the study presents a feasible estimate of the current market scenario, including the Alopecia Treatment market size with regards to value and volume. This extensive report is a gathering of significant data related to the competitive scenario of the industry. Further, it encompasses data with regards to various regions that have successfully established its position in the Alopecia Treatment industry.

Key players profile in the report include (Sales Revenue, Price, Gross Margin, Main Products, etc.):

  • Histogen, Inc.
  • Aclaris Therapeutics, Inc.
  • Concert Pharmaceuticals, Inc.
  • HCell Inc.
  • GlaxoSmithKline Plc.
  • Daiichi Sankyo, Inc.
  • Cipla Limited.

Segmentation of the report:

By Disease Type (Androgenic Alopecia, Alopecia Areata, Ciatricial Alopecia, Traction Alopecia, Alopecia Totalis)

By Drug Type (Vasodilators, 5-Alpha Reductase Inhibitors, Corticosteroids, Immunosuppressants, and Others) By Gender (Male, and Female)

 

By Route of Administration (Oral, Topical, and Injectable)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

By Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa)

 

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Scope of Market:

  • The Alopecia Treatment market report helps in making informed business decisions by having complete insights and by in-depth analysis of market segments
  • It provides a sharp analysis of varying competition dynamics and keeps you ahead of competitors 
  • Analysis of the numerous growth opportunities in the Alopecia Treatment Industry for stakeholders and to offer details of the competitive landscape for noteworthy players
  • Key points related to the focus on the Alopecia Treatment market like the product definition, range of application, revenue and demand and supply statistics.
  • Growth of the Global Alopecia Treatment Market industry across different geographies such as North America, Europe, Asia-Pacific, South America, and Middle East & Africa
  • Competitive Analysis of the top competitors operating in the market along with analyzing the latest trends and business strategies used by various companies.

Alopecia Treatment Market Poised to Grow at a CAGR of XX% Between 2020 – 2030

Source

Previous Posts

Alopecia Treatment Market Insights

Alopecia Treatment Market

Alopecia Treatment Market Poised to Grow at a CAGR of XX% Between 2020 – 2030

Alopecia Treatment Market research report is a professional and an in-depth study available on the market size, share, growth, trends, in addition to industry evaluation. Alopecia Treatment Market report provides a thorough analysis and competitive analysis by region and added main information like a manufacturing process, raw material and equipment suppliers, various manufacturing associated costs, revenue, historical and futuristic cost, demand and supply data.

Moreover, the study presents a feasible estimate of the current market scenario, including the Alopecia Treatment market size with regards to value and volume. This extensive report is a gathering of significant data related to the competitive scenario of the industry. Further, it encompasses data with regards to various regions that have successfully established its position in the Alopecia Treatment industry.

Key players profile in the report include (Sales Revenue, Price, Gross Margin, Main Products, etc.):

  • Histogen, Inc.
  • Aclaris Therapeutics, Inc.
  • Concert Pharmaceuticals, Inc.
  • HCell Inc.
  • GlaxoSmithKline Plc.
  • Daiichi Sankyo, Inc.
  • Cipla Limited.

Segmentation of the report:

By Disease Type (Androgenic Alopecia, Alopecia Areata, Ciatricial Alopecia, Traction Alopecia, Alopecia Totalis)

By Drug Type (Vasodilators, 5-Alpha Reductase Inhibitors, Corticosteroids, Immunosuppressants, and Others) By Gender (Male, and Female)

 

By Route of Administration (Oral, Topical, and Injectable)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

By Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa)

 

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Scope of Market:

  • The Alopecia Treatment market report helps in making informed business decisions by having complete insights and by in-depth analysis of market segments
  • It provides a sharp analysis of varying competition dynamics and keeps you ahead of competitors 
  • Analysis of the numerous growth opportunities in the Alopecia Treatment Industry for stakeholders and to offer details of the competitive landscape for noteworthy players
  • Key points related to the focus on the Alopecia Treatment market like the product definition, range of application, revenue and demand and supply statistics.
  • Growth of the Global Alopecia Treatment Market industry across different geographies such as North America, Europe, Asia-Pacific, South America, and Middle East & Africa
  • Competitive Analysis of the top competitors operating in the market along with analyzing the latest trends and business strategies used by various companies.

Alopecia Treatment Market Poised to Grow at a CAGR of XX% Between 2020 – 2030

Source

Previous Posts

PRP Workshop To Enhance Hair Restoration

Stem Cell and Platelet Rich Plasma Alopecia Therapies

Stem Cell and Platelet Rich Plasma Alopecia Therapies Market Demand, Recent Trends and Developments Analysis 2025

An Up to Date Report on “Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market size | Industry Segment by Applications (Dermatology Clinics and Hospitals), by Type (Platelet Rich Plasma Injections and Stem Cell Therapy), Regional Outlook, Market Demand, Latest Trends, Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts – 2025.” Analyzes current market size and upcoming 5 years growth of this industry.

The recent study on Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market Analysis report provides information about this industry with regards to a thorough assessment of this business. The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market size are appropriately divided into pivotal segments according to the report.

A synopsis of the industry with regards to market size concerning renumeration and volume aspects along with the current Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market shares scenario is offered in the report.

The study on Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market offers information related to the geographical landscape of this vertical along with the forms that have achieved profitable position across the marketplace.

An outline of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market scope

    A synopsis of the competitive landscape

Orange County Hair Restoration Center
Hair Sciences Center of Colorado
Evolution Hair Loss Institute
Savola Aesthetic Dermatology Center
Anderson Center for Hair
Colorado Surgical Center & Hair Institute
Virginia Surgical Center
Hair Transplant Institute of Miami

Analysis of the regional vastness
An outline of the market segmentation

    Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Outlook by Applications:

Dermatology Clinics
Hospitals

    Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Statistics by Types:

Platelet Rich Plasma Injections
Stem Cell Therapy

Synopsis of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market competitive landscape

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market analysis report consists of data regarding the competitive terrain as well as analysis of the competitive scope of this industry.
The competitive influence of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market share spans the firms such as Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Evolution      Hair Loss Institute, Savola Aesthetic Dermatology Center, Anderson Center for Hair, Colorado Surgical Center & Hair Institute, Virginia Surgical Center and Hair Transplant Institute of Miami.
Data about industry participant’s current share in the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market, production sites as well as area served by the participants is mentioned in the report.
Details regarding the manufacturer’s portfolio, product’s application, and features of the product has been cited in the report.
Information about the companies as well as data associated to the profit margins and models is presented in the report.

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Analysis of the regional expanse

The report divides the regional spectrum of the industry significantly.
Data related to the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry share of these regions have been mentioned in the report. Moreover, data related to growth opportunities for companies that have their base in these regions is also highlighted in the report.
Information, in terms of, growth rate that is accounted for by every geography over the estimated time period is specified in the report.

Summary of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market segmentation

The study presents the segments of this vertical with the correct exactness.
The product expanse of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market is split into Platelet Rich Plasma Injections and Stem Cell Therapy. The report presents details about application landscape of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market and is divided into Dermatology Clinics and Hospitals.
Information with regards to industry share amassed by every product segment along with the market value is presented in the report.
Data regarding the production growth is inculcated in the report.
As per the application segment, the report includes information correlated to the market share attained by every application segment.
As per the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Analysis report, data related to the product consumption of every application accompanied by the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market growth rate to be registered by each application segment in the upcoming period is presented in the report.


Stem Cell and Platelet Rich Plasma Alopecia Therapies Market Demand, Recent Trends and Developments Analysis 2025

Source

Previous Posts

Alopecia Treatment Market

Alopecia Treatment Market Growth

Alopecia Treatment Market Growth and Forecast Report, 2020 – 2026

The Global Alopecia Treatment Market research report provides all-inclusive industry research with the latest and astoundingly affirmed sectors. This report covers all the consumption trends and the prominent players with market size, share, growth for the forecast period from 2020-2026.

The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the alopecia treatment market include Capillus, Cipla, Inc., Cirrus Hair Centers, Follica, Inc., Johnson & Johnson Services, Inc., Lexington Intl., LLC, Merck & Co., Inc, Sun Pharmaceuticals Industries Ltd., Transitions Hair, Vita-Cos-Med Klett-Loch GmbH, and others. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.

Market Dynamics

The rising cases of hair loss because of chronic disorders and stress coupled with the advancement in the hair loss treatment are the prominent factors propelling the market growth. Rising disposable income and growing sense of aesthetic appeal are further expected to fuel the market demand. Moreover, the rising number of geriatric population and growing awareness regarding hair loss treatment is also projected to increase the market value. However, the high cost of the treatment is likely to impede market growth.

This detailed market study is centred on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights into the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of alopecia treatment.

Market Segmentation

The broad alopecia treatment market has been sub-grouped into type, end-use, sales channel, and gender. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target a specific market. This detail will lead to a focused approach leading to identification of better opportunities.

By Type

Alopecia Areata
Cicatricial Alopecia
Traction Alopecia
Alopecia Totalis
Alopecia Universalis
Androgenetic Alopecia
Others

By End-Use

Dermatology Clinics
Homecare Setting

By Sales Channel

Prescription
OTC

By Gender

Male
Female

Regional Analysis

Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for alopecia treatment in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.

Alopecia Treatment Market Growth and Forecast Report, 2020 – 2026

Source

Previous Posts

Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

Open Label Trial of CTP-543 in Patients with Alopecia Areata

Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata

Concert Pharmaceuticals, Inc. today announced that it has completed its open label trial evaluating 8 mg twice-daily compared to 16 mg once-daily dosing of CTP-543 in patients with moderate-to-severe alopecia areata. Results in the 8 mg twice-daily arm were consistent with the previously-reported 8 mg twice-daily results from the Company’s Phase 2 trial of CTP-543. Treatment was generally well tolerated in both arms of the study. All but one of the patients who completed this trial have elected to continue in an open-label long-term extension study. The Company expects to report findings from the study at a future medical meeting

“Based on the results observed, the twice-daily regimen is preferred, and we intend to utilize it in our clinical development program for CTP-543 going forward,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “We believe that the findings from our dose regimen studies may be valuable to CTP-543’s intellectual property portfolio and therefore are not disclosing additional data from this study at this time.”

The dose regimen trial (NCT03811912) was a randomized, multi-center study to evaluate the efficacy and tolerability of once-daily versus twice-daily oral dosing of CTP-543, in adult patients with moderate-to-severe alopecia areata. Fifty-seven patients in the trial were randomized to receive CTP-543 either 8 mg twice-daily or 16 mg once-daily over a 24-week treatment period. The trial measured the relative change in Severity of Alopecia Tool (SALT) score between Week 24 and baseline.

Data from the Company’s Phase 2 trials will support an end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to review and discuss the Company’s registration pathway for CTP-543 for the treatment of alopecia areata. The Company expects to meet with the FDA and initiate Phase 3 testing in 2020.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted Fast Track designation for CTP-543 for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata

Source

Previous Posts

Follica Announces Positive Topline Data from Clinical Study in Male Androgenetic Alopecia

Follica Announces Positive Topline Data from Clinical Study in Male Androgenetic Alopecia

Follica Announces Positive Topline Data from Clinical Study in Male Androgenetic Alopecia

Demonstrated 44% improvement over baseline of visible (non-vellus) hair count, a well-established hair growth measure (p value < 0.001)

Study met primary endpoint and identified optimal frequency and number of treatments with Follica’s proprietary device in combination with a topical drug after three months of treatment

Phase 3 registration study initiation expected in first half of 2020

Follica, a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, epithelial aging and other medical indications, today announced topline results from its safety and efficacy optimization study to treat hair loss in male androgenetic alopecia. The study was designed to select the optimal treatment regimen using Follica’s proprietary device in combination with a topical drug and successfully met its primary endpoint.

The selected treatment regimen demonstrated a statistically significant 44% improvement of visible (non-vellus) hair count after three months of treatment compared to baseline (p < 0.001, n = 19).

Across all three treatment arms, the overall improvement of visible (non-vellus) hair count after three months of treatment was 29% compared to baseline (p < 0.001, n = 48), reflecting a clinical benefit across the entire study population and a substantially improved outcome seen with the optimal treatment regimen. Additionally, a prespecified analysis comparing the 44% change in visible (non-vellus) hair count to a 12% historical benchmark set by approved pharmaceutical products1 established statistical significance (p = 0.005). The initiation of a Phase 3 registration study is expected in the first half of 2020.

    “Some of my past life was spent trying to stop hair from growing, but I’m equally enthusiastic to have been involved in helping advance and optimize George Cotsarelis’ key discovery that shows promise for creating new hair”

Follica’s proprietary in-office treatment regimen combines targeted scalp disruption using the Follica Hair Follicle Neogenesis (HFN) device, with a topical on-market drug to create and grow new hair follicles. Based on clinical testing over several years, Follica has optimized a range of important parameters to enable the therapeutic effect. Specifically, Follica’s proprietary HFN device is designed to create new hair follicles and hair on the scalp for the treatment of androgenetic alopecia.

follica

In blinded head-to-head bench testing, the Follica HFN device significantly outperforms available skin disruption devices on key treatment parameters important for hair follicle neogenesis. The topline results from this clinical study, together with three previously conducted clinical trials, provide important validation for Follica’s proprietary approach for the treatment of androgenetic alopecia.

“The topline results of this study represent an exciting potential new treatment to address a persisting challenge in our field: identifying a successful approach to growing new hair in patients who have lost hair,” said Ken Washenik, MD, PhD, president and medical director of Bosley Medical Group, clinical faculty of dermatology at NYU School of Medicine and senior medical advisor to Follica. “We believe Follica is the first to bring forward an approach to grow new hair that is now supported by strong human efficacy data.

The compelling data generated by the company thus far indicate that Follica’s approach could be a promising new option for the approximately 90 million people who are eligible for the treatment of androgenetic alopecia in the United States alone.”

The study involved a less than five-minute in-office experimental scalp procedure using the proprietary Follica HFN device designed to stimulate hair follicle growth and evaluated the optimal frequency and number of treatments across three arms. Follica’s approach is based on generating an “embryonic window” in adults via a series of skin disruptions, stimulating stem cells and causing new hair follicles to grow. This process of hair follicle neogenesis involves minimal daily interruption and is enhanced through the application of a topical compound as part of the treatment regimen following HFN.

“We are very pleased with the results of this study and are especially excited to demonstrate the strength of Follica’s proprietary device and treatment regimen,” said Jason Bhardwaj, chief executive officer of Follica. “Our data show that clinical results differ significantly based on the approach to disrupting the skin and confirm Follica’s proprietary treatment paradigm is optimized for new hair growth. We look forward to initiating the pivotal trial.”

“Some of my past life was spent trying to stop hair from growing, but I’m equally enthusiastic to have been involved in helping advance and optimize George Cotsarelis’ key discovery that shows promise for creating new hair,” said R. Rox Anderson, MD, PhD, professor of dermatology at Harvard Medical School, director of the Massachusetts General Hospital Laser Center and scientific advisor to Follica, who conceived and developed many of the non-scarring treatments now widely used in medical and aesthetic care. These include laser treatments for birthmarks, microvascular and pigmented lesions, tattoo and permanent hair removal, as well as cryolipolysis (Coolsculpting®).

The safety and efficacy optimization study was an endpoint-blinded, randomized, controlled study designed to establish therapeutic parameters for Follica’s proprietary device in combination with a topical drug. The study consisted of 48 men aged 18-40 who had moderate grades of androgenetic alopecia (Hamilton Norwood III-IV). The optimal frequency and number of treatments was studied across three treatment arms. The regimen was well tolerated across all treatment arms with no reported serious adverse events. No adverse events were related to device treatment. A single non-severe event (headache) was determined to be related to use of the drug and is in line with minor side effects seen from treatment with the approved drug alone.

In addition to the safety and efficacy optimization study, Follica has proof-of-concept data from prior clinical studies using prototype devices with different treatment parameters and therapeutic compounds. Follica’s translational work builds on an important basic discovery by George Cotsarelis, MD, chair of the department of dermatology at the University of Pennsylvania and a co-founder of Follica.

About Androgenetic Alopecia

Androgenetic alopecia represents the most common form of hair loss in men and women, with an estimated 90 million people who are eligible for treatment in the United States alone. Only two drugs, both of which have demonstrated a 12% increase of non-vellus hair count over baseline for their primary endpoints, are currently approved for the treatment of androgenetic alopecia1. The most effective current approach for the treatment of hair loss is hair transplant surgery, comprising a range of invasive, expensive procedures for a subset of patients who have enough donor hair to be eligible. As a result, there remains a significant need for safe, effective, non-surgical treatments to grow new hair.

About Follica

Follica is a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, epithelial aging and other medical indications. Founded by PureTech Health (LSE: PRTC), a co-inventor of the current platform, and a group of world-renowned experts in hair follicle biology and regenerative medicine, Follica’s experimental treatment platform has been shown to stimulate the development of new hair follicles and hair in three previously conducted clinical studies.

The company’s proprietary treatment is designed to induce an embryonic window via a device with optimized parameters to initiate hair follicle neogenesis, the formation of new hair follicles from epithelial (skin) stem cells. This process is enhanced through the application of a topical compound. Follica completed an optimization trial and a Phase 3 registration study in androgenetic alopecia is expected to begin in the first half of 2020. Follica’s technology is based on work originating from the University of Pennsylvania that has been further developed by Follica’s internal program. Follica’s extensive IP portfolio includes IP exclusively licensed from the University of Pennsylvania as well as Follica-owned IP.

Source

Previous Posts

Alopecia Treatment Market

Alopecia Treatment Market Size

Alopecia Treatment Market Size, Growth Forecast 2020 to 2025

Latest Report on “Alopecia Treatment Market size | Industry Segment by Applications (Hospitals, Dermatology And Trichology Clinics, Home Care Settings and Other), by Type (Topical Drugs, Oral Drugs, Injectable, Hair Transplant Services and Other), Regional Outlook, Market Demand, Latest Trends, Alopecia Treatment Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts – 2025.” Analyzes current market size and upcoming 5 years growth of this industry.

A comprehensive analysis of the Alopecia Treatment market is presented in this document, along with a brief overview of the segments in the industry. The study presents a feasible estimate of the current market scenario, including the Alopecia Treatment market size with regards to the volume and renumeration.

The report is a collection of significant data related to the competitive landscape of the industry. It also contains data with regards to several regions that have successfully established its position in the Alopecia Treatmentmarket.

Repot Scope:

Alopecia Treatment Market Outlook by Applications:

Hospitals
Dermatology And Trichology Clinics
Home Care Settings
Other

Alopecia Treatment Market Statistics by Types:

Topical Drugs
Oral Drugs
Injectable
Hair Transplant Services
Other

Alopecia Treatment market competition by top Manufacturers:

Teva Pharmaceutical Industries
Merck
Johnson?Johnson
Reddy’s Laboratories
Cipla
Cellmid
Himalaya Drug
Taisho Pharmaceutical Holdings

A Glimpse over the highlights of the report:

The study offers synopsis of product scope of the Alopecia Treatment market. The product range of the Alopecia Treatment market has been further categorized into Topical Drugs, Oral Drugs, Injectable, Hair Transplant Services and Other

Information about the production volume and the price trends are provided in the report.

The study also offers the market share gained by each product type in the Alopecia Treatment market, along with the production growth.

Data related to the Alopecia Treatment market application spectrum is provided, and the application terrain divided into Hospitals, Dermatology And Trichology Clinics, Home Care Settings and Other.

The report also encompasses detailed information of the market share obtained by every application along with the projected growth rate and product consumption of every application.

Data related to market industry concentration rate with respect to the raw materials is present in the report.

Information about the relevant price along with data related to sales together with the projected expansion trends for the Alopecia Treatment market is revealed in the report.

The market study report has been analyzed thoroughly with regards to the marketing strategies, that consist of several marketing channels which producers implement to endorse their products.

Data with respect to marketing channel development trends along with the market position is provided in the report.

Providing a thorough outline of the competitive and regional spheres of the Alopecia Treatment market:

An important evaluation of the competitive landscape of this business is provided in the report.

Crucial data related to the market share accumulated by each company along with facts pertaining to the sales area have been provided in the report.

The study offers a thorough assessment of the products manufactured by the firms, specifications, including their application frame of reference.

Information pertaining a basic outline, profit margins, price prototypes etc. of the companies participating in the Alopecia Treatment market share is also provided.

Details related to every regions market share along with the growth opportunities for each region is inculcated in the report.

The projected growth rate which every region is expected to register over the predicted time period is mentioned in the study.

Alopecia Treatment Market Size, Growth Forecast 2020 to 2025

Source

Previous Posts

Alopecia Treatment Market

Global Androgenic Alopecia Drug Market

Global Androgenic Alopecia Drug Market Report 2019

Global Androgenic Alopecia Drug Market Report 2019With the slowdown in world economic growth, the Androgenic Alopecia Drug industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Androgenic Alopecia Drug market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2018, our analysts believe that in the next few years, Androgenic Alopecia Drug market size will be further expanded, we expect that by 2023, The market size of the Androgenic Alopecia Drug will reach XXX million $.

This Report covers the manufacturers data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better.

This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.

Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value.

Also cover different industries clients information, which is very important for the manufacturers.

Key manufacturers are included based on manufacturing sites, capacity and production, product specifications etc.:

Allergan, Inc.

Histogen, Inc.

R-Tech Ueno, Ltd.

Hygeia Therapeutics, Inc.

SWITCH Biotech LLC

Polichem S.A.

Kasiak Research Pvt. Ltd.

Region Segmentation

North America Country (United States, Canada)

South America

Asia Country (China, Japan, India, Korea)

Europe Country (Germany, UK, France, Italy)

Other Country (Middle East, Africa, GCC)

Product Type Segmentation

RK-023

Refagro

RCH-01

SM-04554

HYG-440

Industry Segmentation

Clinic

Hospital

Home Use

Global Androgenic Alopecia Drug Market Report 2019

Source

Previous Posts

Cassiopea Announces First Patient to be Enrolled in Phase II Trial for Alopecia

Cassiopea Announces First Patient to be Enrolled in Phase II Trial for Alopecia

Cassiopea Announces First Patient to be Enrolled in Phase II Trial for the Treatment of Androgenetic Alopecia in Females with Clascoterone Solution

Cassiopea SpA, a specialty pharmaceutical company focused on developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, announced today that it has received approval from the German Authority BfArM and the coordinating ethical committee and will now proceed to enroll the first patient in a Phase II trial investigating clascoterone solution for the treatment of androgenetic alopecia (AGA) in females.

The Phase II multicenter, prospective, randomized, double-blind, vehicle controlled, dose ranging study will evaluate the efficacy and safety of clascoterone solution for the treatment of AGA in females. The six-month study will enroll approximately 280 female subjects between 18-55 years of age with mild to moderate AGA in Germany.

The four-arm study will enroll 70 subjects per arm in each of four treatment groups: clascoterone solution 5% BID (twice daily), clascoterone solution 7.5% BID (twice daily), minoxidil solution 2% BID (twice daily) and vehicle BID (twice daily). The co-primary endpoints are: (1) change from baseline in non-vellus Target Area Hair Count (TAHC) at month 6 in comparison to vehicle and (2) Hair Growth Assessment (HGA) score at month 6 in comparison to vehicle.

Clascoterone, a new chemical entity, is a proposed first-in-class topical androgen receptor inhibitor currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of acne (in a 1% cream) and in late stage development for the treatment of AGA (in a higher strength solution).

Laboratory studies suggest clascoterone competes with androgens, specifically dihydrotestosterone (DHT), for binding to the androgen receptors within the sebaceous gland and hair follicles. Because of clascoterone’s likely local effect at the site of application, the risk of off-target, or systemic side effects, is minimized.

AGA is a leading cause of hair loss in men and women. In AGA, high local concentrations of DHT bind to androgen receptors within the scalp hair follicles, resulting in shortening of the hair cycle and gradual miniaturization of scalp follicles in men and women with a genetic predisposition.

Over time, these progressively smaller, thinner hair follicles are unable to produce new hair, thus resulting in AGA’s characteristic patterned baldness. DHT dependent effects are considered, in most cases, reversible, such that AGA could be responsive to medical treatment with clascoterone solution through its proposed MOA of direct inhibition of testosterone and DHT binding to local hair follicle androgen receptors. Clascoterone has the potential to be the only topical antiandrogen for use in both men and women with AGA if approved by the FDA.

Based on early clinical review, Cassiopea believes that topical clascoterone will not have the contraindications and safety warnings of an orally administered androgen modulator used for the treatment of AGA in men. It appears Clascoterone does not interfere with the hormonal and, in particular, testosterone profiles of male subjects; libido and sexual behavior changes have not been observed in clinical trials to date. Clascoterone is quickly metabolized to cortexolone, a metabolite with a known safety profile. Due to its rapid metabolism and local activity, there appears to be limited systemic exposure to clascoterone and thus potential systemic side effects are minimized.

On April 16, 2019, Cassiopea announced topline results from the Phase II Dose Ranging trial in males demonstrating statistically significant improvement versus vehicle for TAHC for each dose tested along with directional improvement for HGA at twelve months. No treatment-related serious adverse events among patients were recorded during the trial; local skin reactions, if present, were similar to vehicle and predominantly classified as mild.  Cassiopea has an End of Phase II Meeting with FDA scheduled on November 13, 2019, to discuss the AGA Phase III Program in males with clascoterone solution.

“Clascoterone, a unique topical androgen receptor inhibitor, has shown a remarkable increase in hair growth as compared to vehicle with minimal side effects in the Phase II Dose Ranging Study in males. If FDA approved, it will be a very welcomed and important therapy for female and male patterned hair loss, androgenetic alopecia,” said Wilma Bergfeld, Professor of Dermatology and Pathology at Cleveland Clinic and Past President, American Academy of Dermatology and American Society of Dermatopathology.

“If approved, clascoterone solution will be the first new mechanism of action for the treatment of androgenetic alopecia in decades, offering dermatologists and patients a new and potentially effective therapeutic alternative,” said Diana Harbort, CEO of Cassiopea. “We’re focused on the urgency to treat skin and scalp conditions that can leave not only physical scars, but also emotional scars. That’s why innovation is so critical. We are committed to finding a new pathway to treat the most common form of hair loss affecting both men and women.”

About Cassiopea

Cassiopea is a specialty pharmaceutical company focused on developing and commercializing prescription drugs with novel mechanisms of action to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia and genital warts.

Cassiopea is investing in innovation that is driving scientific advancement in areas that have been largely ignored for decades. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. If approved, Cassiopea plans to commercialize the products directly in the U.S. and partner the products for countries outside of the U.S. For further information on Cassiopea, please visit www.cassiopea.com.

About Clascoterone

Clascoterone, a new chemical entity, is a proposed first in class topical androgen receptor inhibitor under FDA review for the treatment of acne (in a 1% cream) and in late stage development for androgenetic alopecia (in a higher strength solution). Laboratory studies suggest clascoterone competes with androgens, specifically DHT, for binding to the androgen receptors within the sebaceous gland and hair follicles. When applied directly to the skin surface, clascoterone appears to target only local androgen receptors within the skin.  Because of clascoterone’s likely local effect at the site of application, the risk of off-target, or systemic side effects, is minimized.

Next events  

CS Small & Mid Cap Conference, Zurich
November 13, 2019

Jefferies Health Care Conference, London
November 20, 2019

Full-year results 2019
February 2020

Some of the information contained in this press release may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cassiopea has no obligation to publicly update or revise any forward-looking statements.

Cassiopea Announces First Patient to be Enrolled in Phase II Trial for the Treatment of Androgenetic Alopecia in Females with Clascoterone Solution

Source

Previous Posts

PRP Workshop To Enhance Hair Restoration

Platelet Rich Plasma Alopecia Therapies

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size,Status and Forecast 2019-2025

Platelet-rich plasma (PRP) has emerged as a new treatment modality in regenerative plastic surgery, and preliminary evidence suggests that it might have a beneficial role in hair regrowth.
In 2018, the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies status, future forecast, growth opportunity, key market and key players.

The study objectives are to present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Orange County Hair Restoration Center
Hair Sciences Center of Colorado
Anderson Center for Hair
Evolution Hair Loss Institute
Savola Aesthetic Dermatology Center
Virginia Surgical Center
Hair Transplant Institute of Miami
Colorado Surgical Center & Hair Institute

Market segment by Type, the product can be split into

Platelet Rich Plasma Injections
Stem Cell Therapy

Market segment by Application, split into

Dermatology Clinics
Hospitals

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies status, future forecast, growth opportunity, key market and key players.
To present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies are as follows:

History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size,Status and Forecast 2019-2025

Source

Previous Posts

Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata

Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented results from its recently completed Phase 2 dose-ranging trial of the investigational medicine CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss.

Patients in the study treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 met the primary efficacy endpoint with statistically significant differences (p <0.001) relative to placebo in the percentage of patients achieving a ≥ 50% relative change from baseline at 24 weeks using the Severity of Alopecia Tool (SALT). These results were presented during the 28th European Academy of Dermatology and Venereology (EADV) Annual Congress in Madrid, Spain.

    “We look forward to advancing the development of CTP-543 into Phase 3 evaluation next year, as we continue our efforts to bring a new treatment to patients with this serious autoimmune disorder that currently has no approved medications.”

“We are very pleased that we were selected to present our safety and efficacy data for CTP-543 to the treatment community at this Congress. We believe the results from this dose-ranging study with our oral JAK inhibitor, CTP-543, set a new bar for clinical results in patients with moderate-to-severe alopecia areata,” stated James V. Cassella, Ph.D., Concert’s Chief Development Officer, who made the oral presentation at EADV. “We look forward to advancing the development of CTP-543 into Phase 3 evaluation next year, as we continue our efforts to bring a new treatment to patients with this serious autoimmune disorder that currently has no approved medications.”

In the Phase 2 trial, the primary efficacy endpoint in the 12 mg twice-daily cohort was met with 58% of patients achieving a ≥ 50% relative reduction in their overall SALT score from baseline compared to 9% for placebo (p <0.001), with statistically significant separation from placebo occurring at Week 12.

In the 8 mg twice-daily cohort, 47% of patients achieved the primary endpoint compared to placebo (p <0.001). For the 4 mg cohort, 21% of patients achieved a ≥ 50% relative reduction in their overall SALT score from baseline, however there was not a statistically significant difference from placebo.

Data from the Patient Global Impression of Improvement scale showed 78% of the patients receiving 12 mg twice-daily and 58% of the patients receiving 8 mg twice-daily rated their alopecia areata as “much improved” or “very much improved” at Week 24. For both doses there was a statistically significant difference from placebo (p <0.001).

In the Phase 2 trial, the most common (≥10%) side effects in the 12 mg CTP-543 dose group were headache, nasopharyngitis, upper respiratory tract infection and acne.

One serious adverse event of facial cellulitis was reported as possibly related to treatment. After a brief dosing interruption, treatment was continued and this patient completed the trial. No thromboembolic events were reported during the trial.

The Phase 2 trial was a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata. A total of 149 patients were randomized to receive one of three doses of CTP-543 (4 mg, 8 mg, or 12 mg) or placebo, administered twice-daily.

The primary outcome measure utilized the SALT score after 24 weeks of dosing. The average baseline SALT score across all patients was approximately 88%, where 0% is no scalp hair loss and 100% represents total scalp hair loss. All patients who completed 24 weeks of treatment in the 12 mg dosing cohort had the opportunity to continue in a separate extension study to evaluate long-term safety and efficacy of CTP-543.

Details from the oral presentation, entitled “CTP-543, an oral JAK inhibitor, achieves primary endpoint in Phase 2 randomized, placebo-controlled, dose ranging trial in patients with moderate-to-severe alopecia areata,” is available in the Scientific Presentations section of Concert’s website.

About CTP-543 and Alopecia Areata

CTP-543 is an oral inhibitor of Janus kinases JAK1 and JAK2 for the potential treatment of alopecia areata. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 650,000 Americans at any given time1.

The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI was to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs.

The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.

Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress

Source

Previous Posts